|
1
|
Sacco AG and Cohen EE: Current treatment
options for recurrent or metastatic head and neck squamous cell
carcinoma. J Clin Oncol. 33:3305–3313. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burtness B, Harrington KJ, Greil R,
Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane
P, Bratland Å, et al: Pembrolizumab alone or with chemotherapy
versus cetuximab with chemotherapy for recurrent or metastatic
squamous cell carcinoma of the head and neck (KEYNOTE-048): A
randomised, open-label, phase 3 study. Lancet. 394:1915–1928. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gillison ML, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE,
Even C, et al: CheckMate 141: 1-Year update and subgroup analysis
of nivolumab as first-line therapy in patients with
recurrent/metastatic head and neck cancer. Oncologist.
23:1079–1082. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun C, Mezzadra R and Schumacher TN:
Regulation and function of the PD-L1 checkpoint. Immunity.
48:434–452. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pai SI, Zandberg DP and Strome SE: The
role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck
cancer treatment. Oral Oncol. 61:152–158. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Keck MK, Zuo Z, Khattri A, Stricker TP,
Brown CD, Imanguli M, Rieke D, Endhardt K, Fang P, Brägelmann J, et
al: Integrative analysis of head and neck cancer identifies two
biologically distinct HPV and three non-HPV subtypes. Clin Cancer
Res. 21:870–881. 2015. View Article : Google Scholar
|
|
8
|
Seiwert TY, Burtness B, Mehra R, Weiss J,
Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, et
al: Safety and clinical activity of pembrolizumab for treatment of
recurrent or metastatic squamous cell carcinoma of the head and
neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial.
Lancet Oncol. 17:956–965. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chow LQM, Haddad R, Gupta S, Mahipal A,
Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, et al:
Antitumor activity of pembrolizumab in biomarker-unselected
patients with recurrent and/or metastatic head and neck squamous
cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion
cohort. J Clin Oncol. 34:3838–3845. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Soulieres D, Cohen E, Le Tourneau C, Dinis
J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, et al:
Abstract CT115: Updated survival results of the KEYNOTE-040 study
of pembrolizumab vs standard-of-care chemotherapy for recurrent or
metastatic head and neck squamous cell carcinoma. Cancer Res. 78(13
Suppl): CT1152018. View Article : Google Scholar
|
|
11
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar
|
|
12
|
Gavrielatou N, Doumas S, Economopoulou P,
Foukas PG and Psyrri A: Biomarkers for immunotherapy response in
head and neck cancer. Cancer Treat Rev. 84:1019772020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ludwig S, Floros T, Theodoraki MN, Hong
CS, Jackson EK, Lang S and Whiteside TL: Suppression of lymphocyte
functions by plasma exosomes correlates with disease activity in
patients with head and neck cancer. Clin Cancer Res. 23:4843–4854.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cocucci E and Meldolesi J: Ectosomes and
exosomes: Shedding the confusion between extracellular vesicles.
Trends Cell Biol. 25:364–372. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
van der Pol E, Böing AN, Harrison P, Sturk
A and Nieuwland R: Classification, functions, and clinical
relevance of extracellular vesicles. Pharmacol Rev. 64:676–705.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ludwig S, Sharma P, Wise P, Sposto R,
Hollingshead D, Lamb J, Lang S, Fabbri M and Whiteside TL: mRNA and
miRNA profiles of exosomes from cultured tumor cells reveal
biomarkers specific for HPV16-positive and HPV16-negative head and
neck cancer. Int J Mol Sci. 21:85702020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ludwig S, Marczak L, Sharma P, Abramowicz
A, Gawin M, Widlak P, Whiteside TL and Pietrowska M: Proteomes of
exosomes from HPV(+) or HPV(-) head and neck cancer cells:
Differential enrichment in immunoregulatory proteins.
Oncoimmunology. 8:15938082019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Theodoraki MN, Yerneni SS, Hoffmann TK,
Gooding WE and Whiteside TL: Clinical significance of
PD-L1+ exosomes in plasma of head and neck cancer
patients. Clin Cancer Res. 24:896–905. 2018. View Article : Google Scholar
|
|
19
|
Theodoraki MN, Laban S, Jackson EK, Lotfi
R, Schuler PJ, Brunner C, Hoffmann TK, Whiteside TL and Hofmann L:
Changes in circulating exosome molecular profiles following
surgery/(chemo)radiotherapy: Early detection of response in head
and neck cancer patients. Br J Cancer. 125:1677–1686. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jablonska J, Rist M, Spyra I, Tengler L,
Domnich M, Kansy B, Giebel B, Thakur BK, Rotter N, Lang S and
Ludwig S: Evaluation of immunoregulatory biomarkers on plasma small
extracellular vesicles for disease progression and early
therapeutic response in head and neck cancer. Cells. 11:9022022.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Daassi D, Mahoney KM and Freeman GJ: The
importance of exosomal PDL1 in tumour immune evasion. Nat Rev
Immunol. 20:209–215. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gandara DR, Paul SM, Kowanetz M,
Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G,
Malboeuf C, et al: Blood-based tumor mutational burden as a
predictor of clinical benefit in non-small-cell lung cancer
patients treated with atezolizumab. Nat Med. 24:1441–1448. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rückert M, Flohr AS, Hecht M and Gaipl US:
Radiotherapy and the immune system: More than just immune
suppression. Stem Cells. 39:1155–1165. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hecht M, Fietkau R and Gaipl US:
Definitive chemoradiotherapy of locally advanced head and neck
cancer in combination with immune checkpoint inhibition-new
concepts required. Strahlenther Onkol. 198:83–85. 2022.In German.
View Article : Google Scholar
|
|
25
|
Welters MJ, Fichtinger-Schepman AM, Baan
RA, Hermsen MA, van der Vijgh WJ, Cloos J and Braakhuis BJ:
Relationship between the parameters cellular differentiation,
doubling time and platinum accumulation and cisplatin sensitivity
in a panel of head and neck cancer cell lines. Int J Cancer.
71:410–415. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Affolter A, Muller MF, Sommer K,
Stenzinger A, Zaoui K, Lorenz K, Wolf T, Sharma S, Wolf J, Perner
S, et al: Targeting irradiation-induced mitogen-activated protein
kinase activation in vitro and in an ex vivo model for human head
and neck cancer. Head Neck. 38(Suppl 1): E2049–E2061. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hong CS, Funk S, Muller L, Boyiadzis M and
Whiteside TL: Isolation of biologically active and morphologically
intact exosomes from plasma of patients with cancer. J Extracell
Vesicles. 5:292892016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rajamoorthi A, Shrivastava S, Steele R,
Nerurkar P, Gonzalez JG, Crawford S, Varvares M and Ray RB: Bitter
melon reduces head and neck squamous cell carcinoma growth by
targeting c-Met signaling. PLoS One. 8:e780062013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chu SC, Hsieh YS, Yu CC, Lai YY and Chen
PN: Thymoquinone induces cell death in human squamous carcinoma
cells via caspase activation-dependent apoptosis and LC3-II
activation-dependent autophagy. PLoS One. 9:e1015792014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chien MH, Yang WE, Yang YC, Ku CC, Lee WJ,
Tsai MY, Lin CW and Yang SF: Dual targeting of the p38 MAPK-HO-1
axis and cIAP1/XIAP by demethoxycurcumin triggers caspase-mediated
apoptotic cell death in oral squamous cell carcinoma cells. Cancers
(Basel). 12:7032020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chung EJ, Brown AP, Asano H, Mandler M,
Burgan WE, Carter D, Camphausen K and Citrin D: In vitro and in
vivo radio-sensitization with AZD6244 (ARRY-142886), an inhibitor
of mitogen-activated protein kinase/extracellular signal-regulated
kinase 1/2 kinase. Clin Cancer Res. 15:3050–3057. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Leiker AJ, DeGraff W, Choudhuri R, Sowers
AL, Thetford A, Cook JA, Van Waes C and Mitchell JB: Radiation
enhancement of head and neck squamous cell carcinoma by the dual
PI3K/mTOR inhibitor PF-05212384. Clin Cancer Res. 21:2792–2801.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Affolter A, Drigotas M, Fruth K,
Schmidtmann I, Brochhausen C, Mann WJ and Brieger J: Increased
radioresistance via G12S K-Ras by compensatory upregulation of MAPK
and PI3K pathways in epithelial cancer. Head Neck. 35:220–228.
2013. View Article : Google Scholar
|
|
34
|
Affolter A, Fruth K, Brochhausen C,
Schmidtmann I, Mann WJ and Brieger J: Activation of
mitogen-activated protein kinase extracellular signal-related
kinase in head and neck squamous cell carcinomas after irradiation
as part of a rescue mechanism. Head Neck. 33:1448–1457. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Affolter A, Samosny G, Heimes AS,
Schneider J, Weichert W, Stenzinger A, Sommer K, Jensen A, Mayer A,
Brenner W, et al: Multikinase inhibitors sorafenib and sunitinib as
radiosensitizers in head and neck cancer cell lines. Head Neck.
39:623–632. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Théry C, Witwer KW, Aikawa E, Alcaraz MJ,
Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F,
Atkin-Smith GK, et al: Minimal information for studies of
extracellular vesicles 2018 (MISEV2018): A position statement of
the international society for extracellular vesicles and update of
the MISEV2014 guidelines. J Extracell Vesicles. 7:15357502018.
View Article : Google Scholar
|
|
37
|
Ock CY, Kim S, Keam B, Kim S, Ahn YO,
Chung EJ, Kim JH, Kim TM, Kwon SK, Jeon YK, et al: Changes in
programmed death-ligand 1 expression during cisplatin treatment in
patients with head and neck squamous cell carcinoma. Oncotarget.
8:97920–97927. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Barker HE, Paget JTE, Khan AA and
Harrington KJ: The tumour microenvironment after radiotherapy:
Mechanisms of resistance and recurrence. Nat Rev Cancer.
15:409–425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dovedi SJ, Adlard AL, Lipowska-Bhalla G,
McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M,
Stewart R, et al: Acquired resistance to fractionated radiotherapy
can be overcome by concurrent PD-L1 blockade. Cancer Res.
74:5458–5468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hirsch L, Zitvogel L, Eggermont A and
Marabelle A: PD-Loma: A cancer entity with a shared sensitivity to
the PD-1/PD-L1 pathway blockade. Br J Cancer. 120:3–5. 2019.
View Article : Google Scholar :
|
|
41
|
Kong Y, Ma Y, Zhao X, Pan J, Xu Z and
Zhang L: Optimizing the treatment schedule of radiotherapy combined
with anti-PD-1/PD-L1 immunotherapy in metastatic cancers. Front
Oncol. 11:6388732021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Narits J, Tamm H and Jaal J: PD-L1
induction in tumor tissue after hypofractionated thoracic
radiotherapy for non-small cell lung cancer. Clin Transl Radiat
Oncol. 22:83–87. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kordbacheh T, Honeychurch J, Blackhall F,
Faivre-Finn C and Illidge T: Radiotherapy and anti-PD-1/PD-L1
combinations in lung cancer: Building better translational research
platforms. Ann Oncol. 29:301–310. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wimmer S, Deloch L, Hader M, Derer A,
Grottker F, Weissmann T, Hecht M, Gostian AO, Fietkau R, Frey B and
Gaipl US: Hypofractionated radiotherapy upregulates several immune
checkpoint molecules in head and neck squamous cell carcinoma cells
independently of the HPV status while ICOS-L is upregulated only on
HPV-positive cells. Int J Mol Sci. 22:91142021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kikuchi M, Clump DA, Srivastava RM, Sun L,
Zeng D, Diaz-Perez JA, Anderson CJ, Edwards WB and Ferris RL:
Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1
monoclonal antibody for assessing radiation-induced PD-L1
upregulation in head and neck cancer and melanoma. Oncoimmunology.
6:e13290712017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Schulz D, Stancev I, Sorrentino A, Menevse
AN, Beckhove P, Brockhoff G, Hautmann MG, Reichert TE, Bauer RJ and
Ettl T: Increased PD-L1 expression in radioresistant HNSCC cell
lines after irradiation affects cell proliferation due to
inactivation of GSK-3beta. Oncotarget. 10:573–583. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mutschelknaus L, Peters C, Winkler K,
Yentrapalli R, Heider T, Atkinson MJ and Moertl S: Exosomes derived
from squamous head and neck cancer promote cell survival after
ionizing radiation. PLoS One. 11:e01522132016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Taube JM, Klein A, Brahmer JR, Xu H, Pan
X, Kim JH, Chen L, Pardoll DM, Topalian SL and Anders RA:
Association of PD-1, PD-1 ligands, and other features of the tumor
immune microenvironment with response to anti-PD-1 therapy. Clin
Cancer Res. 20:5064–5074. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Snyder A, Makarov V, Merghoub T, Yuan J,
Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et
al: Genetic basis for clinical response to CTLA-4 blockade in
melanoma. N Engl J Med. 371:2189–2199. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ribas A and Hu-Lieskovan S: What does
PD-L1 positive or negative mean? J Exp Med. 213:2835–2840. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Derer A, Spiljar M, Bäumler M, Hecht M,
Fietkau R, Frey B and Gaipl US: Chemoradiation increases PD-L1
expression in certain melanoma and glioblastoma cells. Front
Immunol. 7:6102016. View Article : Google Scholar
|
|
52
|
Oweida A, Lennon S, Calame D, Korpela S,
Bhatia S, Sharma J, Graham C, Binder D, Serkova N, Raben D, et al:
Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint
blockade in orthotopic murine head and neck squamous cell
carcinoma. Oncoimmunology. 6:e13561532017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Deng L, Liang H, Burnette B, Beckett M,
Darga T, Weichselbaum RR and Fu YX: Irradiation and anti-PD-L1
treatment synergistically promote antitumor immunity in mice. J
Clin Invest. 124:687–695. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhang B, Bowerman NA, Salama JK, Schmidt
H, Spiotto MT, Schietinger A, Yu P, Fu YX, Weichselbaum RR, Rowley
DA, et al: Induced sensitization of tumor stroma leads to
eradication of established cancer by T cells. J Exp Med. 204:49–55.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lin W, Chen M, Hong L, Zhao H and Chen Q:
Crosstalk between PD-1/PD-L1 blockade and its combinatorial
therapies in tumor immune microenvironment: A focus on HNSCC. Front
Oncol. 8:5322018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Rossi G, Russo A, Tagliamento M, Tuzi A,
Nigro O, Vollome G Sini C, Grassi M, Bello MGD, Coco S, et al:
Präzisionsmedizin bei NSCLC im zeitalter der immuntherapie: Neue
biomarker zur selektion der am besten geeigneten therapie oder des
am besten geeigneten patienten. Kompass Pneumol. 8:300–317. 2020.
View Article : Google Scholar
|
|
57
|
Müller T, Braun M, Dietrich D, Aktekin S,
Höft S, Kristiansen G, Göke F, Schröck A, Brägelmann J, Held SAE,
et al: PD-L1: A novel prognostic biomarker in head and neck
squamous cell carcinoma. Oncotarget. 8:52889–52900. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Balermpas P, Rödel F, Krause M, Linge A,
Lohaus F, Baumann M, Tinhofer I, Budach V, Sak A, Stuschke M, et
al: The PD-1/PD-L1 axis and human papilloma virus in patients with
head and neck cancer after adjuvant chemoradiotherapy: A
multicentre study of the German cancer consortium radiation
oncology group (DKTK-ROG). Int J Cancer. 141:594–603. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hong AM, Ferguson P, Dodds T, Jones D, Li
M, Yang J and Scolyer RA: Significant association of PD-L1
expression with human papillomavirus positivity and its prognostic
impact in oropharyngeal cancer. Oral Oncol. 92:33–39. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chen G, Huang AC, Zhang W, Zhang G, Wu M,
Xu W, Yu Z, Yang J, Wang B, Sun H, et al: Exosomal PD-L1
contributes to immunosuppression and is associated with anti-PD-1
response. Nature. 560:382–386. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Cordonnier M, Nardin C, Chanteloup G,
Derangere V, Algros MP, Arnould L, Garrido C, Aubin F and Gobbo J:
Tracking the evolution of circulating exosomal-PD-L1 to monitor
melanoma patients. J Extracell Vesicles. 9:17108992020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
da Silva JL, Dos Santos ALS, Nunes NCC, de
Moraes Lino da Silva F, Ferreira CGM and de Melo AC: Cancer
immunotherapy: The art of targeting the tumor immune
microenvironment. Cancer Chemother Pharmacol. 84:227–240. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Theodoraki MN, Yerneni S, Gooding WE, Ohr
J, Clump DA, Bauman JE, Ferris RL and Whiteside TL: Circulating
exosomes measure responses to therapy in head and neck cancer
patients treated with cetuximab, ipilimumab, and IMRT.
Oncoimmunology. 8:15938052019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ota K, Azuma K, Kawahara A, Hattori S,
Iwama E, Tanizaki J, Harada T, Matsumoto K, Takayama K, Takamori S,
et al: Induction of PD-L1 expression by the EML4-ALK oncoprotein
and downstream signaling pathways in non-small cell lung cancer.
Clin Cancer Res. 21:4014–4021. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Han JJ, Kim DW, Koh J, Keam B, Kim TM,
Jeon YK, Lee SH, Chung DH and Heo DS: Change in PD-L1 expression
after acquiring resistance to gefitinib in EGFR-mutant
non-small-cell lung cancer. Clin Lung Cancer. 17:263–270.e2. 2016.
View Article : Google Scholar
|
|
66
|
Ebert PJR, Cheung J, Yang Y, McNamara E,
Hong R, Moskalenko M, Gould SE, Maecker H, Irving BA, Kim JM, et
al: MAP kinase inhibition promotes T cell and anti-tumor activity
in combination with PD-L1 checkpoint blockade. Immunity.
44:609–621. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Jiang X, Zhou J, Giobbie-Hurder A, Wargo J
and Hodi FS: The activation of MAPK in melanoma cells resistant to
BRAF inhibition promotes PD-L1 expression that is reversible by MEK
and PI3K inhibition. Clin Cancer Res. 19:598–609. 2013. View Article : Google Scholar
|
|
68
|
Derer A, Frey B, Fietkau R and Gaipl US:
Immune-modulating properties of ionizing radiation: Rationale for
the treatment of cancer by combination radiotherapy and immune
checkpoint inhibitors. Cancer Immunol Immunother. 65:779–786. 2016.
View Article : Google Scholar
|
|
69
|
Burnette BC, Liang H, Lee Y, Chlewicki L,
Khodarev NN, Weichselbaum RR, Fu YX and Auh SL: The efficacy of
radiotherapy relies upon induction of type I interferon-dependent
innate and adaptive immunity. Cancer Res. 71:2488–2496. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Lee Y, Auh SL, Wang Y, Burnette B, Wang Y,
Meng Y, Beckett M, Sharma R, Chin R, Tu T, et al: Therapeutic
effects of ablative radiation on local tumor require
CD8+ T cells: changing strategies for cancer treatment.
Blood. 114:589–595. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Lugade AA, Moran JP, Gerber SA, Rose RC,
Frelinger JG and Lord EM: Local radiation therapy of B16 melanoma
tumors increases the generation of tumor antigen-specific effector
cells that traffic to the tumor. J Immunol. 174:7516–7523. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Dewan MZ, Galloway AE, Kawashima N,
Dewyngaert JK, Babb JS, Formenti SC and Demaria S: Fractionated but
not single-dose radiotherapy induces an immune-mediated abscopal
effect when combined with anti-CTLA-4 antibody. Clin Cancer Res.
15:5379–5388. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Rong C, Muller MF, Xiang F, Jensen A,
Weichert W, Major G, Plinkert PK, Hess J and Affolter A: Adaptive
ERK signalling activation in response to therapy and in silico
prognostic evaluation of EGFR-MAPK in HNSCC. Br J Cancer.
123:288–297. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Fournel L, Wu Z, Stadler N, Damotte D,
Lococo F, Boulle G, Ségal-Bendirdjian E, Bobbio A, Icard P,
Trédaniel J, et al: Cisplatin increases PD-L1 expression and
optimizes immune check-point blockade in non-small cell lung
cancer. Cancer Lett. 464:5–14. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Park SJ, Ye W, Xiao R, Silvin C, Padget M,
Hodge JW, Van Waes C and Schmitt NC: Cisplatin and oxaliplatin
induce similar immunogenic changes in preclinical models of head
and neck cancer. Oral Oncol. 95:127–135. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Tran L, Allen CT, Xiao R, Moore E, Davis
R, Park SJ, Spielbauer K, Van Waes C and Schmitt NC: Cisplatin
alters antitumor immunity and synergizes with PD-1/PD-L1 inhibition
in head and neck squamous cell carcinoma. Cancer Immunol Res.
5:1141–1151. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Varayathu H, Sarathy V, Thomas BE, Mufti
SS and Naik R: Combination strategies to augment immune check point
inhibitors efficacy-implications for translational research. Front
Oncol. 11:5591612021. View Article : Google Scholar
|
|
78
|
Califano JA, Khan Z, Noonan KA, Rudraraju
L, Zhang Z, Wang H, Goodman S, Gourin CG, Ha PK, Fakhry C, et al:
Tadalafil augments tumor specific immunity in patients with head
and neck squamous cell carcinoma. Clin Cancer Res. 21:30–38. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Merlano MC, Merlotti AM, Licitra L, Denaro
N, Fea E, Galizia D, Di Maio M, Fruttero C, Curcio P, Vecchio S, et
al: Activation of immune responses in patients with
relapsed-metastatic head and neck cancer (CONFRONT phase I-II
trial): Multimodality immunotherapy with avelumab, short-course
radiotherapy, and cyclophosphamide. Clin Transl Radiat Oncol.
12:47–52. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Kim JE, Patel MA, Mangraviti A, Kim ES,
Theodros D, Velarde E, Liu A, Sankey EW, Tam A, Xu H, et al:
Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation
results in regression of murine gliomas. Clin Cancer Res.
23:124–136. 2017. View Article : Google Scholar :
|
